---
schema_version: "secwatch.filing_event.v1"
accession: "0001645113-26-000043"
form_type: "8-K"
ticker: "NVCR"
cik: "0001645113"
company_name: "NovoCure Ltd"
filed_at: "2026-04-30T23:59:59+00:00"
generated_at: "2026-05-15T00:58:19.899556+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Novocure Q1 net revenue $174M (+12% YoY); raises FY2026 guidance; Optune Pax launch

## Summary
- Net loss of $71.1M ($0.62 per share); Adjusted EBITDA of -$0.3M.
- Gross margin improved to 78% (from 75%) on lower array costs.
- Optune Pax FDA approved for locally advanced pancreatic cancer; 169 prescriptions, 83 active patients as of March 31, 2026.
- FY2026 revenue guidance raised to $690M-$710M (from $675M-$705M); Adj. EBITDA guidance narrowed to -$15M-$0M.
- PANOVA-4 Phase 2 met primary endpoint with 74% disease control rate vs 48% historical control.

## SEC filing metadata
- accession: 0001645113-26-000043
- form_type: 8-K
- ticker: NVCR
- cik: 0001645113
- company_name: NovoCure Ltd
- filed_at: 2026-04-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000043/0001645113-26-000043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000043/nvcr-20260430.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645113-26-000043
- JSON: https://secwatch.observer/filing/0001645113-26-000043.json
- Plain text: https://secwatch.observer/filing/0001645113-26-000043.txt

## Key facts
- Earnings Releases
  NovoCure Ltd reported first quarter ended March 31, 2026 results: revenue Total net revenues for the quarter were $174.1 million, net income Net loss for the quarter was $71.1 million, EPS loss per share of $0.62.
  - Period: first quarter ended March 31, 2026
  - Revenue: Total net revenues for the quarter were $174.1 million
  - Net income: Net loss for the quarter was $71.1 million
  - EPS: loss per share of $0.62
  - Result: reported results
  source text: Novocure Reports First Quarter 2026 Financial Results Quarterly net revenues of $174 million, up 12% year-over-year, driven by global growth in Optune Gio ® Optune Pax® approved by the U.S. FDA and launched for the treatment of locally advanced pancreatic cancer; more than 800 prescribers certified and more than 160 prescriptions received through March 31, 2026 BAAR, Switzerland – April 30, 2026 - Novocure (NASDAQ: NVCR) today reported financial results for the first quarter that ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000043/0001645113-26-000043-index.htm
- Earnings Releases
  NovoCure Ltd reported full year 2026 results: revenue Total net revenue: $690 million - $710 million (previous: $675 million - $705 million). Guidance raised.
  - Period: full year 2026
  - Revenue: Total net revenue: $690 million - $710 million (previous: $675 million - $705 million)
  - Guidance: raised
  - Result: guidance update
  source text: Novocure’s updated guidance for the full year 2026, as of April 30, 2026, is summarized below: • Total net revenue: $690 million - $710 million (previous: $675 million - $705 million) • Adjusted EBITDA*: $(15) million - $0 million (previous: $(20) million - $0 million)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000043/0001645113-26-000043-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.